

Fact Sheet

SCHWARZ PHARMA develops and markets innovative drugs with a focus on the therapeutic areas of neurology and urology.

In 2004 the company achieved global sales of €947 million, with 78% of this from markets outside Germany. SCHWARZ PHARMA increased expenditures for research and development to €198 million, advancing the development of innovative drugs for the treatment of Parkinson's disease, Restless Legs Syndrome, epilepsy, neuropathic pain and overactive bladder syndrome and others. These expenditures are funded by own cash flow, which in 2004 achieved a level of €47 million.

SCHWARZ PHARMA AG is a public traded company, which:

- has a strong multinational marketing presence and infrastructure that includes affiliates in the U.S., Europe and Asia as well as license agreements in more than 50 countries
- operates GMP manufacturing facilities in the U.S., Europe and Asia
- employs around 4,000 professionals worldwide

In place of cost-intensive and basic research which carries a higher degree of risk, SCHWARZ PHARMA actively seeks partnerships with research companies, pharmaceutical companies, research organizations and universities. SCHWARZ PHARMA prefers innovative project opportunities at clinical stage and offers strong clinical and regulatory capabilities, proven marketing support and expertise in managing international development alliances.

SCHWARZ PHARMA has more than 500 professionals in drug development and regulatory affairs. All development projects are coordinated globally from bases in Monheim, (Germany), Shannon (Ireland), Research Triangle Park, North Carolina (USA) and Tokyo (Japan). The group undertakes worldwide search activities, as well as preclinical, pharmaceutical and clinical drug development and regulatory affairs.

The company has a proven track record that includes four U.S. NDA's in four years as well as multiple approvals across Europe. In September 2004 and January 2005, respectively, SCHWARZ PHARMA submitted marketing applications for rotigotine transdermal system to the European and U.S. regulatory authorities.

SCHWARZ PHARMA is headquartered in Monheim/Germany.

Recent Key Events

December: Rotigotine in Advanced Parkinson's Disease Shows Positive Trial Results

Phase III trial results shows statistically significant and clinically relevant reduction in 'off' time. The results support the favorable data of previous trials with rotigotine.

December: Neupro® Receives Positive Opinion from European CHMP for the Treatment of Early Parkinson's Disease

Clinical trials have shown efficacy and safety in early Parkinson's disease patients and a potential for long term benefit. First market launches of the Parkinson's patch within Europe will be in the first half of 2006.

October: Nine Months Report 2005: Positive Business Trend Continues

In the first nine months of this year, the SCHWARZ PHARMA Group increased sales by 1.5% to €722.3 million. The acquisition of the future rotigotine royalties in July of this year led to an operating result of €23.2 million, and a net result of €48.4 million. After adjustment for this transaction, SCHWARZ PHARMA would have achieved an operating income of €39.8 million and a net income of €8.5 million.

September: Phase III Data for Rotigotine in Advanced Parkinson's Disease at EFNS Congress in Athens

SCHWARZ PHARMA presents a broad spectrum of scientific data from various neurology projects at the 9th EFNS congress in Athens/Greece.

August: SCHWARZ PHARMA to present Lacosamide Data on World Congress of Pain in Sydney

SCHWARZ PHARMA presents data of lacosamide for the treatment of diabetic neuropathic pain at the 11th World Congress on Pain in Sydney/Australia.

August: Positive Data from Phase III Program for Lacosamide:

Lacosamide showed significant reduction in diabetic neuropathic pain combined with good tolerability. 90% of patients decided to continue treatment with lacosamide in open-label follow-on trials. Another clinical trial is expected to report in the second quarter 2006.

SCHWARZ PHARMA Financial Information

2004 Sales		share
Europe	€ 512m	54%
thereof Germany	€ 211m	22%
USA	€ 403m	43%
Asia	€ 31m	3%
Total	€ 947m	100%

SCHWARZ PHARMA shares (ISIN: DE 000 722 190 5) are traded on the Frankfurt (SRZG.F) and Duesseldorf (SRZG.D) Stock Exchanges.
The company's ADR program (one-for-one; SWTZY) is managed by JPMorgan Chase Bank, New York, N.Y., USA

35% of shares are free float, 5% are held by Schroder Investment Management Ltd. The remaining 60% of shares are held by the Schwarz family. Number of shares outstanding: 46.3 million

Major Products Marketed by SCHWARZ PHARMA

Therapeutic Area	Leading Products (most are ®)	2004 Sales €m
Cardiovascular Diseases (coronary heart disease, angina pectoris, hypertension, heart failure, peripheral arterial occlusive disease etc.)	e.g.: Univasc, Uniretic, Verelan PM, Isoket/Dilatrate, Deponit, Elantan, Prostavasin, Provas/Miten, Clivarina	390.5
Gastrointestinal Diseases (ulcer reflux esophagitis, irritable bowel syndrome, dermatoses, bowel cleansing, nausea etc.)	e.g.: generic omeprazole Rifun, Norpramin, Procto, Levsin, Colyte	346.2
Urological Diseases (erectile dysfunction, benign prostatic hyperplasia etc.)	e.g.: Viridal/Edex, Harzol, Mitem	37.6
Central Nervous System Diseases (migraine, pain, sleep disturbances, anxiety etc.)	e.g.: Tylex, Seglor/Agit, Lorans, Naramig	48.4
Other Diseases (iron deficiency, allergies, asthma etc.)	e.g.: Ferro Sanol, Zolim, Atmadisc	123.8

Clinical Development Projects SCHWARZ PHARMA Group

Project	Proposed Indication / Status	Partner	Territory
Rotigotine	Once-a-day patch for Parkinson's Disease / Filing	Otsuka, Japan	Worldwide
Lacosamide	Diabetic neuropathic pain / Phase III	Harris FRC, USA	Worldwide excl. Japan
Lacosamide	Epilepsy / Phase III	Harris FRC, USA	Worldwide excl. Japan
Rotigotine	Restless Legs Syndrome (RLS) / Phase III	Otsuka, Japan	Worldwide
Rotigotine Nasal Spray	Acute Symptoms of Parkinson's Disease / Phase I completed	Otsuka, Japan	Worldwide
Fesoterodine	Overactive bladder syndrome / urinary incontinence / Phase III completed		Worldwide

Contact:

Corporate Communications SCHWARZ PHARMA AG, Alfred-Nobel-Strasse 10, 40789 Monheim, Germany

Tel +49 2173 48 1377; Fax: +49 2173 48 1856

info@schwarzpharma.com; www.schwarzpharma.com